<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451227</url>
  </required_header>
  <id_info>
    <org_study_id>13-6972-B</org_study_id>
    <nct_id>NCT03451227</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures</brief_title>
  <official_title>A Pilot Study to Investigate the Efficacy and Safety of Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures for Treatment of a Tachyarrhythmia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of dexmedetomidine and compare this to a current
      technique commonly used at TGH for sedation in patients undergoing ablation procedures for
      atrial fibrillation (AF) and atrial flutter.

      The investigators hypothesise that dexmedetomidine will be at least equivalent to, or more
      so, in terms of effectiveness and safety, when compared to midazolam and remifentanil for
      sedation during ablation procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of ablation for chronic persistent AF has been debated amongst cardiologists for
      some time, and there is increasing evidence that ablation may be superior to medical
      management. As populations age, the rate of AF is likely to increase and therefore the
      numbers of ablations performed for this arrhythmia will also be expected to increase.

      Ablation procedures can vary in length from one to more than 6 hours in duration and require
      the patient to keep still so as not to influence the mapping procedure.

      Options for anaesthesia care include a general anaesthetic or sedation. Several studies have
      evaluated the safety of sedation for ablation, using combinations of fentanyl, midazolam and
      propofol. These demonstrate that the ablation procedures are well tolerated under deep
      sedation.

      Dexmedetomidine is an attractive potential agent for this role due to its favourable
      respiratory pharmacodynamics and good sedation profile. Dexmedetomidine is a short acting
      relatively specific alpha-2 receptor agonist (alpha 2: alpha 1 = 1300:1). It has been shown
      to have very little effect on respiratory parameters, even at high doses.In addition, it may
      offer some analgesic properties and therefore minimise the need for narcotic based agents.
      the investigators will compare dexmedetomidine infusion and fentanyl bolus with remifentanil
      infusion midazolam bolus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single blind, randomised controlled study looking at the feasibility of dexmedetomidine for sedation during ablation procedures at Toronto General Hospital.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patients will be randomly allocated (computer generated) to receive either a dexmedetomidine infusion or a remifentanil infusion.
The patient, interventional cardiologist and data analyser will be blinded to the drugs given. The anaesthesia care provider will not be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of haemodynamic events requiring intervention</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>a.Hypotension i. A decrease of 30% or more from baseline ii. Or absolute cut off values of
SBP &lt; 80mmHg
DBP &lt;40mmHg iii. Number of events and total dose of phenylephrine or ephedrine administered.
b. Hypertension i. An increase in Systolic blood pressure 30% or more from baseline ii. Or an absolute cut off value of &gt; 180mmHg iii. Total number of events c. Bradycardia i. A decrease of 30% or more from baseline ii. Or absolute cut off values of &lt; 40bpm iii. Total number of events and total dose of glycopyrolate or atropine administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of respiratory events requiring intervention</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Respiratory events requiring intervention
Respiratory rate &lt; 6 breaths/min
Airway obstruction requiring manual support
Airway obstruction requiring guedel insertion
Apnoea (cessation of respiration &gt;10seconds)
Hypoxia (saturations &lt;90% for &gt;20 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative pain scores</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>VAS score (visual analog score). VAS is a simple assessment tool consisting of a 10 cm line with 0 on one end, representing no pain, and 10 on the other, representing the worst pain ever experienced, which a patient indicates so the clinician knows the severity of his or her pain. Pain scores using a VAS scale ranging from zero to ten will be recorded every 30 minutes
Total amount of additional fentanyl used intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative sedation scores</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Sedation Agitation Scale (SAS) scale range from 1 to 7 will be recorded every 5 minutes. The SAS scale is outlined below with an optimal score of 4 for procedural sedation.
Ref: Riker RR, Picard JT and Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Critical Care Medicine 1999;27(7):1325-1329.
Total amount of additional midazolam used intraoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Assessed with the Iowa Satisfaction with Anaesthesia scale 24 hours post procedure b. Assessor blinded to technique c. To include direct questioning regarding the patients willingness to undergo the same procedure again using the same technique
Iowa Satisfaction with Anaesthesia scale
Ref: Dexter F, Aker J, Wright W. Development of a measure of patient satisfaction with monitored anaesthetic care: the Iowa Satisfaction with Anesthesia Scale. Anesthesiology 1997; 87: 865-73.
Patient assessment
I threw up or felt like throwing up
I would have the same anaesthetic again
I itched
I felt relaxed
I felt pain
I felt safe
I was too hot or cold
I was satisfied with the anesthesia care
I felt pain during the surgery
I felt good
I hurt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Time from stopping infusion to a SAS score of â‰¥4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the recovery unit</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Total time spent in recovery until appropriate discharge criteria are met and patient is discharged to the ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia requirements</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Quantity of opioids required i. Intraoperatively ii. In recovery iii. In the first 24 hours post op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative nausea and vomiting (PONV)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Subjective or objective evidence of PONV lasting &gt; 30 mins
Antiemetic therapy administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Any complaints of itch during the procedure and 24 hours post operatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine group</intervention_name>
    <description>The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.</description>
    <arm_group_label>Dexmedetomidine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Group</intervention_name>
    <description>Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.</description>
    <arm_group_label>Remifentanil Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients listed for an ablation procedure for treatment of atrial fibrillation or
             flutter at TGH requiring sedation provided by an anesthetist

          -  Valid consent

        Exclusion Criteria:

          -  Baseline HR &lt;40

          -  Baseline SBP &lt; 80mmHg

          -  Baseline SBP &gt; 180mmHg

          -  Second or third degree heart block unless pacemaker in situ

          -  Uncontrolled heart failure/severe LV dysfunction (Ejection fraction &lt; 40%)

          -  Severe hepatic dysfunction (Transaminases greater than 2 times the upper limit of
             normal)

          -  Renal dysfunction: estimated GFR &lt; 30ml/min, or requiring dialysis

          -  Allergy to any of the study drugs (dexmedetomidine, remifentanil, fentanyl, midazolam)

          -  Cognitive impairment precluding ability to tolerate sedation and comply with
             assessment methods

          -  Requirement for general anaesthetic for the procedure

          -  Pregnancy or breast feeding mothers

          -  Chronic use or addiction to opioids

          -  &lt; 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Djaiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital, University Health Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jo Carroll</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>jo.carroll@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto General Hospital, Univerity health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Djaiani, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>6205</phone_ext>
      <email>george.djaiani@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Verma A, Natale A. Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients. Circulation. 2005 Aug 23;112(8):1214-22; discussion 1231. Review.</citation>
    <PMID>16116072</PMID>
  </reference>
  <reference>
    <citation>Di Biase L, Santangeli P, Natale A. How to ablate long-standing persistent atrial fibrillation? Curr Opin Cardiol. 2013 Jan;28(1):26-35. doi: 10.1097/HCO.0b013e32835b59bb. Review.</citation>
    <PMID>23207492</PMID>
  </reference>
  <reference>
    <citation>Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8. doi: 10.1161/CIRCEP.109.859116. Epub 2009 Dec 7.</citation>
    <PMID>19995881</PMID>
  </reference>
  <reference>
    <citation>Drabek T, NÄ›mec J. Anesthetic management of electrophysiological procedures for heart failure. Int Anesthesiol Clin. 2012 Summer;50(3):22-42. doi: 10.1097/AIA.0b013e3182603e95. Review.</citation>
    <PMID>22735718</PMID>
  </reference>
  <reference>
    <citation>Di Biase L, Conti S, Mohanty P, Bai R, Sanchez J, Walton D, John A, Santangeli P, Elayi CS, Beheiry S, Gallinghouse GJ, Mohanty S, Horton R, Bailey S, Burkhardt JD, Natale A. General anesthesia reduces the prevalence of pulmonary vein reconnection during repeat ablation when compared with conscious sedation: results from a randomized study. Heart Rhythm. 2011 Mar;8(3):368-72. doi: 10.1016/j.hrthm.2010.10.043. Epub 2010 Nov 2.</citation>
    <PMID>21055479</PMID>
  </reference>
  <reference>
    <citation>Di Biase L, Saenz LC, Burkhardt DJ, Vacca M, Elayi CS, Barrett CD, Horton R, Bai R, Siu A, Fahmy TS, Patel D, Armaganijan L, Wu CT, Kai S, Ching CK, Phillips K, Schweikert RA, Cummings JE, Arruda M, Saliba WI, Dodig M, Natale A. Esophageal capsule endoscopy after radiofrequency catheter ablation for atrial fibrillation: documented higher risk of luminal esophageal damage with general anesthesia as compared with conscious sedation. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):108-12. doi: 10.1161/CIRCEP.108.815266. Epub 2009 Feb 13.</citation>
    <PMID>19808454</PMID>
  </reference>
  <reference>
    <citation>Wutzler A, Rolf S, Huemer M, Parwani AS, Boldt LH, Herberger E, Hohenbichler K, Dietz R, Haverkamp W. Safety aspects of deep sedation during catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2012 Jan;35(1):38-43. doi: 10.1111/j.1540-8159.2011.03260.x. Epub 2011 Nov 6.</citation>
    <PMID>22054234</PMID>
  </reference>
  <reference>
    <citation>Kottkamp H, Hindricks G, Eitel C, MÃ¼ller K, Siedziako A, Koch J, Anastasiou-Nana M, Varounis C, Arya A, Sommer P, Gaspar T, Piorkowski C, Dagres N. Deep sedation for catheter ablation of atrial fibrillation: a prospective study in 650 consecutive patients. J Cardiovasc Electrophysiol. 2011 Dec;22(12):1339-43. doi: 10.1111/j.1540-8167.2011.02120.x. Epub 2011 Jun 21.</citation>
    <PMID>21692895</PMID>
  </reference>
  <reference>
    <citation>Salukhe TV, Willems S, Drewitz I, Steven D, Hoffmann BA, Heitmann K, Rostock T. Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. Europace. 2012 Mar;14(3):325-30. doi: 10.1093/europace/eur328. Epub 2011 Oct 23.</citation>
    <PMID>22024600</PMID>
  </reference>
  <reference>
    <citation>Bhananker SM, Posner KL, Cheney FW, Caplan RA, Lee LA, Domino KB. Injury and liability associated with monitored anesthesia care: a closed claims analysis. Anesthesiology. 2006 Feb;104(2):228-34.</citation>
    <PMID>16436839</PMID>
  </reference>
  <reference>
    <citation>Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010 Jan 1;110(1):47-56. doi: 10.1213/ane.0b013e3181ae0856. Epub 2009 Aug 27.</citation>
    <PMID>19713256</PMID>
  </reference>
  <reference>
    <citation>Khan ZP, Ferguson CN, Jones RM. alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999 Feb;54(2):146-65. Review.</citation>
    <PMID>10215710</PMID>
  </reference>
  <reference>
    <citation>Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992 Dec;77(6):1125-33.</citation>
    <PMID>1361310</PMID>
  </reference>
  <reference>
    <citation>Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705.</citation>
    <PMID>10702460</PMID>
  </reference>
  <reference>
    <citation>Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000 Aug;93(2):382-94.</citation>
    <PMID>10910487</PMID>
  </reference>
  <reference>
    <citation>Ryu JH, Lee SW, Lee JH, Lee EH, Do SH, Kim CS. Randomized double-blind study of remifentanil and dexmedetomidine for flexible bronchoscopy. Br J Anaesth. 2012 Mar;108(3):503-11. doi: 10.1093/bja/aer400. Epub 2011 Dec 15.</citation>
    <PMID>22174346</PMID>
  </reference>
  <reference>
    <citation>Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg. 2004 Jan;98(1):153-8, table of contents.</citation>
    <PMID>14693611</PMID>
  </reference>
  <reference>
    <citation>Cortinez LI, Hsu YW, Sum-Ping ST, Young C, Keifer JC, Macleod D, Robertson KM, Wright DR, Moretti EW, Somma J. Dexmedetomidine pharmacodynamics: Part II: Crossover comparison of the analgesic effect of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004 Nov;101(5):1077-83.</citation>
    <PMID>15505442</PMID>
  </reference>
  <reference>
    <citation>Kaygusuz K, Gokce G, Gursoy S, Ayan S, Mimaroglu C, Gultekin Y. A comparison of sedation with dexmedetomidine or propofol during shockwave lithotripsy: a randomized controlled trial. Anesth Analg. 2008 Jan;106(1):114-9, table of contents. doi: 10.1213/01.ane.0000296453.75494.64.</citation>
    <PMID>18165564</PMID>
  </reference>
  <reference>
    <citation>Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology. 2004 Sep;101(3):744-52.</citation>
    <PMID>15329600</PMID>
  </reference>
  <reference>
    <citation>Talke P, Li J, Jain U, Leung J, Drasner K, Hollenberg M, Mangano DT. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. Anesthesiology. 1995 Mar;82(3):620-33.</citation>
    <PMID>7879930</PMID>
  </reference>
  <reference>
    <citation>Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002 Aug;95(2):461-6, table of contents.</citation>
    <PMID>12145072</PMID>
  </reference>
  <reference>
    <citation>Hogue CW Jr, Talke P, Stein PK, Richardson C, Domitrovich PP, Sessler DI. Autonomic nervous system responses during sedative infusions of dexmedetomidine. Anesthesiology. 2002 Sep;97(3):592-8.</citation>
    <PMID>12218525</PMID>
  </reference>
  <reference>
    <citation>Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003 Feb;29(2):201-7. Epub 2002 Nov 22.</citation>
    <PMID>12594584</PMID>
  </reference>
  <reference>
    <citation>Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M, Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology. 2005 Aug;103(2):269-73.</citation>
    <PMID>16052108</PMID>
  </reference>
  <reference>
    <citation>Hsu YW, Cortinez LI, Robertson KM, Keifer JC, Sum-Ping ST, Moretti EW, Young CC, Wright DR, Macleod DB, Somma J. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology. 2004 Nov;101(5):1066-76.</citation>
    <PMID>15505441</PMID>
  </reference>
  <reference>
    <citation>Alhashemi JA. Dexmedetomidine vs midazolam for monitored anaesthesia care during cataract surgery. Br J Anaesth. 2006 Jun;96(6):722-6. Epub 2006 Apr 4.</citation>
    <PMID>16595611</PMID>
  </reference>
  <reference>
    <citation>Vann MA, Ogunnaike BO, Joshi GP. Sedation and anesthesia care for ophthalmologic surgery during local/regional anesthesia. Anesthesiology. 2007 Sep;107(3):502-8. Review.</citation>
    <PMID>17721254</PMID>
  </reference>
  <reference>
    <citation>Cheung CW, Ying CL, Chiu WK, Wong GT, Ng KF, Irwin MG. A comparison of dexmedetomidine and midazolam for sedation in third molar surgery. Anaesthesia. 2007 Nov;62(11):1132-8.</citation>
    <PMID>17924894</PMID>
  </reference>
  <reference>
    <citation>Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg. 2008 Jun;106(6):1784-6. doi: 10.1213/ane.0b013e318172fafc.</citation>
    <PMID>18499610</PMID>
  </reference>
  <reference>
    <citation>McCutcheon CA, Orme RM, Scott DA, Davies MJ, McGlade DP. A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg. 2006 Mar;102(3):668-75.</citation>
    <PMID>16492813</PMID>
  </reference>
  <reference>
    <citation>Rozet I, Muangman S, Vavilala MS, Lee LA, Souter MJ, Domino KJ, Slimp JC, Goodkin R, Lam AM. Clinical experience with dexmedetomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg. 2006 Nov;103(5):1224-8.</citation>
    <PMID>17056959</PMID>
  </reference>
  <reference>
    <citation>Okawa K, Ichinohe T, Kaneko Y. A comparison of propofol and dexmedetomidine for intravenous sedation: a randomized, crossover study of the effects on the central and autonomic nervous systems. Anesth Analg. 2010 Feb 1;110(2):415-8. doi: 10.1213/ANE.0b013e3181c88ba0. Epub 2009 Dec 10.</citation>
    <PMID>20007736</PMID>
  </reference>
  <reference>
    <citation>Tsai CJ, Chu KS, Chen TI, Lu DV, Wang HM, Lu IC. A comparison of the effectiveness of dexmedetomidine versus propofol target-controlled infusion for sedation during fibreoptic nasotracheal intubation. Anaesthesia. 2010 Mar;65(3):254-9. doi: 10.1111/j.1365-2044.2009.06226.x. Epub 2010 Jan 22.</citation>
    <PMID>20105150</PMID>
  </reference>
  <reference>
    <citation>DupanoviÄ‡ M, Lakkireddy D, Emert MP, Krebill R. Utility of dexmedetomidine in sedation for radiofrequency ablation of atrial fibrillation. J Perianesth Nurs. 2013 Jun;28(3):144-50. doi: 10.1016/j.jopan.2012.10.005.</citation>
    <PMID>23711310</PMID>
  </reference>
  <reference>
    <citation>Prachanpanich N, Apinyachon W, Ittichaikulthol W, Moontripakdi O, Jitaree A. A comparison of dexmedetomidine and propofol in Patients undergoing electrophysiology study. J Med Assoc Thai. 2013 Mar;96(3):307-11.</citation>
    <PMID>23539933</PMID>
  </reference>
  <reference>
    <citation>Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med. 1999 Jul;27(7):1325-9.</citation>
    <PMID>10446827</PMID>
  </reference>
  <reference>
    <citation>Dexter F, Aker J, Wright WA. Development of a measure of patient satisfaction with monitored anesthesia care: the Iowa Satisfaction with Anesthesia Scale. Anesthesiology. 1997 Oct;87(4):865-73.</citation>
    <PMID>9357889</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Jo Carroll</investigator_full_name>
    <investigator_title>Manager Anesthesia Research</investigator_title>
  </responsible_party>
  <keyword>Sedation, Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

